Clinical trials: Paclitaxel, completed
Ovarian Cancer, Fallopian Tube Cancer
Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
Investigators hypothesize that concurrent ribociclib treatment and chemotherapy will enhance the response to platinum-based therapy and maintenance therapy will slow ovarian cancer tumor growth leading to prolongation in…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
- Trial name
- NCT03056833
- Testing
- ribociclib, Paclitaxel, Carboplatin
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- Ronald Buckanovich
Cancer, Tumor
Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors
This is a study evaluating the safety and effectiveness of Combretastatin A4 Phosphate (CA4P) combined with the chemotherapy drugs, carboplatin and paclitaxel. The full treatment and observation time should be about 5 months.
- Trial name
- NCT00113438
- Testing
- Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mateon Therapeutics
Endometrial Cancer, Papillary Serous
Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
The purpose of this study is to determine the progression-free survival of patients with surgically staged, Stage I-II papillary serous, clear cell, or endometrioid carcinomas with high-intermediate risk factors treated by…
- Conditions
- Endometrial Cancer, Papillary Serous, Clear Cell Endometrial Cancer
- Trial name
- NCT00542490
- Testing
- Vaginal Cuff Brachytherapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Oklahoma
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer
This phase II trial studies how well giving paclitaxel albumin-stabilized nanoparticle (Nab-paclitaxel) formulation together with bevacizumab followed by bevacizumab and erlotinib hydrochloride work in treating patients with…
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT00733408
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, erlotinib hydrochloride
- Where
- 17 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of Washington
Ovarian Cancer
A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer
This single arm study evaluated the efficacy and safety of first-line chemotherapy with carboplatin and dose-dense weekly paclitaxel plus bevacizumab (Avastin) in participants with epithelial ovarian, fallopian tube, or primary…
- Trial name
- NCT00937560
- Testing
- Bevacizumab, Paclitaxel, Carboplatin
- Where
- 55 sites in Brazil, France and 7 more
- Volunteers
- 190 people
- Sponsor
- Hoffmann-La Roche
Early Stage Breast Cancer
Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer
This research study is testing the safety and feasibility of delivering the 4 cycles of 'dose-dense' paclitaxel without the use of Neulasta (Pegfilgrastim) as a Granulocyte Colony-stimulating Factor (G-CSF) support.
- Trial name
- NCT02698891
- Testing
- Paclitaxel, Neulasta
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Dana-Farber Cancer Institute
Biliary Cancer Metastatic
Bevacizumab Plus Nab-paclitaxel and Tegafur Gimeracil Oteracil Potassium Capsule (S-1) as Second-line Treatment for Advanced Biliary Tract Cancer: a Phase Ⅱ Clinical Trial
This prospective, single-center, single-arm phase II clinical trial was designed to evaluate the efficacy and safety of bevacizumab plus nab-paclitaxel and S-1 as second-line treatment for patients with advanced biliary tract…
- Trial name
- NCT07719738
- Testing
- Bevacizumab+nab-paclitaxel+tegafur gimeracil oteracil potassium capsule (S-1)
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Breast Cancer, Locally Advanced Breast Cancer
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
This is a Phase IIIb, multinational, multicenter, randomized, open-label study to evaluate patient preference of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous use (PH FDC SC) administration in the home…
- Conditions
- Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer
- Trial name
- ProHer (NCT05415215)
- Testing
- Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC), Pertuzumab IV, Trastuzumab IV
- Where
- 45 sites in Argentina, Bosnia and Herzegovina and 15 more
- Volunteers
- 346 people
- Sponsor
- Hoffmann-La Roche
Fallopian Tube Cancer, Ovarian Cancer
Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00028743
- Testing
- carboplatin, cisplatin, paclitaxel
- Where
- 28 sites in Canada
- Volunteers
- 819 people
- Sponsor
- NCIC Clinical Trials Group
Lung Cancer
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003317
- Testing
- carboplatin, paclitaxel, radiation therapy
- Where
- 16 sites in United States
- Volunteers
- 480 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Ovarian Cancer, Primary Peritoneal Cancer
Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian
The purpose of this study is to determine the maximum tolerated dose (MTD) of intravenous weekly paclitaxel given with intravenous carboplatin and bevacizumab in patients with epithelial ovarian, primary peritoneal, or fallopian…
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT01219777
- Testing
- carboplatin, Bevacizumab, Paclitaxel
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Ritu Salani
Esophageal Squamous Cell Carcinoma
Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC
The purpose of this study is to observe and evaluate the efficacy and safety of A sintilimab plus chemotherapy followed by definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT03985046
- Testing
- Sintilimab plus Chemotherapy
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Fudan University
Peripheral Vascular Disease
Drug-Coated Chocolate PTA Balloon in Patients With Peripheral Arterial Disease - The ENDURE Trial
This first-in-man study is to evaluate the Drug-Coated Chocolate (DCC) Balloon for percutaneous arterial angioplasty in patients with symptomatic peripheral arterial disease.
- Trial name
- ENDURE (NCT02129127)
- Testing
- Paclitaxel Coated Chocolate Balloon Angioplasty
- Where
- 2 sites in Germany, New Zealand
- Volunteers
- 67 people
- Sponsor
- TriReme Medical, LLC
Squamous Cell Carcinoma of the Head and Neck
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck
This study is being done to test whether panitumumab, in combination with chemotherapy and radiation is safe in people with head and neck cancer.
- Trial name
- NCT00513383
- Testing
- Panitumumab, Carboplatin, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Non Small Cell Lung Cancer
Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel
The purpose of this research study is to test the effectiveness of three treatment arms that are designed to improve survival in patients with non-small cell lung cancer.
- Trial name
- NCT02684461
- Testing
- Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Coronary Artery Disease, Coronary Restenosis
Clinical Performance of the Pantera Lux Balloon Versus the Orsiro Stent in Patients With In-stent Restenosis.
To determine in a randomized controlled trial (RCT) whether percutaneous coronary intervention - in patients with in-stent restenosis in either bare metal stents or drug eluting stents - with the Pantera Lux balloon is…
- Trial name
- BIOLUX-RCT (NCT01651390)
- Testing
- Percutaneous coronary intervention
- Where
- 14 sites in Germany, Latvia
- Volunteers
- 231 people
- Sponsor
- Biotronik AG
Ovarian Cancer, Fallopian Tube Cancer
Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
The purpose of this research study is to evaluate how patients with newly diagnosed advanced ovarian, fallopian tube, primary peritoneal cancer and papillary serous or clear cell mullerian tumors respond to consolidation therapy…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Papillary Serous Mullerian Tumor
- Trial name
- NCT00520013
- Testing
- bevacizumab, erlotinib, paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Dana-Farber Cancer Institute
Carcinoma, Non-Small-Cell Lung, Metastatic Lung Cancer
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)
AIO-YMO/TRK-0416 (DURATION) is a open-label, treatment stratified and randomized phase II study of Durvalumab, frail or elderly patients with metastatic non-squamous NSCLC with no targetable molecular alterations (EGFRwt…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Metastatic Lung Cancer, Non Small Cell Lung Cancer, Lung Adenocarcinoma Metastatic
- Trial name
- DURATION (NCT03345810)
- Testing
- Durvalumab, Vinorelbine, Gemcitabine
- Where
- 30 sites in Germany
- Volunteers
- 200 people
- Sponsor
- AIO-Studien-gGmbH
Breast Cancer
Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients
This is a multicenter, open-label, phase II trial to assess the efficacy of the GAT neoadjuvant regimen in patients with stage III breast cancer.
- Trial name
- NCT00128856
- Testing
- Gemcitabine, Adriamycine, Paclitaxel
- Where
- 10 sites in Spain
- Volunteers
- 46 people
- Sponsor
- Spanish Breast Cancer Research Group
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma
First-line Chemotherapy for Recurrent Cervical Cancer
The response rate of traditional first-line chemotherapy for recurrent or persistent advanced cervical cancer was low. This single arm, open, phase II trial would recruit 37 eligible patients.
- Conditions
- Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy, Vascular Endothelial Growth Factor 2 Inhibitor
- Trial name
- NCT04188847
- Testing
- Chemotherapy plus apatinib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Lei Li
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.